These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

303 related items for PubMed ID: 16595597

  • 41. Sulfonylurea improves CNS function in a case of intermediate DEND syndrome caused by a mutation in KCNJ11.
    Mlynarski W, Tarasov AI, Gach A, Girard CA, Pietrzak I, Zubcevic L, Kusmierek J, Klupa T, Malecki MT, Ashcroft FM.
    Nat Clin Pract Neurol; 2007 Nov; 3(11):640-5. PubMed ID: 17982434
    [Abstract] [Full Text] [Related]

  • 42. Metabolic control in type 2 diabetes is associated with sulfonylurea receptor-1 (SUR-1) but not with KCNJ11 polymorphisms.
    Nikolac N, Simundic AM, Katalinic D, Topic E, Cipak A, Zjacic Rotkvic V.
    Arch Med Res; 2009 Jul; 40(5):387-92. PubMed ID: 19766903
    [Abstract] [Full Text] [Related]

  • 43. Impact of sulfonylurea receptor 1 genetic variability on non-insulin-dependent diabetes mellitus prevalence and treatment: a population study.
    Meirhaeghe A, Helbecque N, Cottel D, Arveiler D, Ruidavets JB, Haas B, Ferrières J, Tauber JP, Bingham A, Amouyel P.
    Am J Med Genet; 2001 Jun 01; 101(1):4-8. PubMed ID: 11343328
    [Abstract] [Full Text] [Related]

  • 44. Minireview: pharmacogenetics and beyond: the interaction of therapeutic response, beta-cell physiology, and genetics in diabetes.
    Hattersley AT, Pearson ER.
    Endocrinology; 2006 Jun 01; 147(6):2657-63. PubMed ID: 16556760
    [Abstract] [Full Text] [Related]

  • 45.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 46.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 47.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 48.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 49. Prediabetes is associated with genetic variations in the gene encoding the Kir6.2 subunit of the pancreatic ATP-sensitive potassium channel (KCNJ11): A case-control study in a Han Chinese youth population.
    Xu M, Hu H, Deng D, Chen M, Xu Z, Wang Y.
    J Diabetes; 2018 Feb 01; 10(2):121-129. PubMed ID: 28449408
    [Abstract] [Full Text] [Related]

  • 50. Ser1369Ala variant in sulfonylurea receptor gene ABCC8 is associated with antidiabetic efficacy of gliclazide in Chinese type 2 diabetic patients.
    Feng Y, Mao G, Ren X, Xing H, Tang G, Li Q, Li X, Sun L, Yang J, Ma W, Wang X, Xu X.
    Diabetes Care; 2008 Oct 01; 31(10):1939-44. PubMed ID: 18599530
    [Abstract] [Full Text] [Related]

  • 51.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 52. The effect of KCNJ11 polymorphism on the risk of type 2 diabetes: a global meta-analysis based on 49 case-control studies.
    Gong B, Yu J, Li H, Li W, Tong X.
    DNA Cell Biol; 2012 May 01; 31(5):801-10. PubMed ID: 22082043
    [Abstract] [Full Text] [Related]

  • 53.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 54.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 55. The KCNJ11 E23K polymorphism and progression of glycaemia in Southern Chinese: a long-term prospective study.
    Cheung CY, Tso AW, Cheung BM, Xu A, Fong CH, Ong KL, Law LS, Wat NM, Janus ED, Sham PC, Lam KS.
    PLoS One; 2011 May 01; 6(12):e28598. PubMed ID: 22163043
    [Abstract] [Full Text] [Related]

  • 56. Effect of genetic polymorphisms on the development of secondary failure to sulfonylurea in egyptian patients with type 2 diabetes.
    El-Sisi AE, Hegazy SK, Metwally SS, Wafa AM, Dawood NA.
    Ther Adv Endocrinol Metab; 2011 Aug 01; 2(4):155-64. PubMed ID: 23148181
    [Abstract] [Full Text] [Related]

  • 57. The first case report of sulfonylurea use in a woman with permanent neonatal diabetes mellitus due to KCNJ11 mutation during a high-risk pregnancy.
    Klupa T, Kozek E, Nowak N, Cyganek K, Gach A, Milewicz T, Czajkowski K, Tolloczko J, Mlynarski W, Malecki MT.
    J Clin Endocrinol Metab; 2010 Aug 01; 95(8):3599-604. PubMed ID: 20466780
    [Abstract] [Full Text] [Related]

  • 58. The carriage of risk variants of CDKAL1 impairs beta-cell function in both diabetic and non-diabetic patients and reduces response to non-sulfonylurea and sulfonylurea agonists of the pancreatic KATP channel.
    Chistiakov DA, Potapov VA, Smetanina SA, Bel'chikova LN, Suplotova LA, Nosikov VV.
    Acta Diabetol; 2011 Sep 01; 48(3):227-35. PubMed ID: 21611789
    [Abstract] [Full Text] [Related]

  • 59.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 60.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 16.